SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group is a late-stage clinical biopharmaceutical company developing cancer therapeutics. Its product candidates are galinpepimut-S, or GPS, a peptide immunotherapy targeting the WT1 antigen, and SLS009, a selective small-molecule CDK9 inhibitor. The company is headquartered in New York, NY. SELLAS is developing GPS as a monotherapy and in combination with other agents for blood cancers and solid tumors. Its ongoing Phase 3 REGAL study evaluates GPS as maintenance treatment for patients with acute myeloid leukemia after a second complete remission. SLS009 is being studied for AML and other cancers, including in a Phase 2 trial in newly diagnosed patients. SELLAS holds rights to develop and commercialize GPS and GPS+ in Greater China through a license agreement, while retaining rights elsewhere. It licenses worldwide SLS009 rights except in Greater China. The agreements provide for upfront and milestone payments, with potential future royalties under the GPS license.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $SLS in the last 30 days.
See all $SLS insider activity →Sellas Life Sciences (SLS) stock rose 0.4% overnight after Citigroup cut its stake by 64%, while retail investors highlighted the potential value of SLS009. SLS009 showed 34% response rate in a Phase 2 AML study, with higher rates in specific subtypes. Sellas also expects Phase 2 and Phase 3 trial results this quarter. SLS stock is up 142% year-to-date.
Sellas Life Sciences (SLS) shares rose 4% to $8.70, ending a four-day slide, as investors await abstracts from the American Society of Hematology (ASH) meeting. Institutional investors, including Pictet and Arizona State Retirement System, increased their stakes in Q3. Sellas expects Q4 topline results from its Phase 2 study of SLS009 in AML. The company also announced its Phase 3 Regal trial has reached a critical milestone, with preliminary results expected this quarter.
Sellas (SLS) fell 17.2% this week after a key trial milestone. ImmunityBio (IBRX) declined despite FDA approvals. Ionis (IOVA) also slumped. SLS CEO called the milestone critical, but results are pending. IBRX has a Q4 FDA submission planned. Retail sentiment varied; all three stocks outperformed XBI this year.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning SLS (SELLAS Life Sciences Group, Inc.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent SLS coverage spans financial news, technology and market movers.
Stake reduction may weigh on shares, but positive trial data could boost upside.
Anticipation of trial data and institutional buying likely supports short-term upside.
The trial milestone triggered a sharp sell‑off as investors await efficacy data.
The milestone could drive the stock higher if the upcoming data show survival benefit.
The approaching Phase 3 trigger is a material clinical milestone that could drive the stock higher if data are positive.
AlphAI scores every news story that mentions SLS with an AI model for sentiment and relevance, and aggregates insider trades from SELLAS Life Sciences Group, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Sellas Life Sciences (SLS) stock rose 0.4% overnight after Citigroup cut its stake by 64%, while retail investors highlighted the potential value of SLS009. SLS009 showed 34% response rate in a Phase 2 AML study, with higher rates in specific subtypes. Sellas also expects Phase 2 and Phase 3 trial results this quarter. SLS stock is up 142% year-to-date.
Sellas Life Sciences (SLS) shares rose 4% to $8.70, ending a four-day slide, as investors await abstracts from the American Society of Hematology (ASH) meeting. Institutional investors, including Pictet and Arizona State Retirement System, increased their stakes in Q3. Sellas expects Q4 topline results from its Phase 2 study of SLS009 in AML. The company also announced its Phase 3 Regal trial has reached a critical milestone, with preliminary results expected this quarter.
Sellas (SLS) fell 17.2% this week after a key trial milestone. ImmunityBio (IBRX) declined despite FDA approvals. Ionis (IOVA) also slumped. SLS CEO called the milestone critical, but results are pending. IBRX has a Q4 FDA submission planned. Retail sentiment varied; all three stocks outperformed XBI this year.
SELLAS Life Sciences (NASDAQ:SLS) announced its Phase 3 REGAL trial for galinpepimut-S in AML patients reached the 80th event, triggering final analysis. The company plans to release topline results this quarter. Galinpepimut-S targets the WT1 protein and is being evaluated for maintenance therapy in AML. SELLAS also develops SLS009, a CDK9 inhibitor for AML.
SELLAS Life Sciences (SLS) is approaching the 80-death event trigger for its Phase 3 REGAL trial and continues enrollment in the Phase 2 SLS009 trial, with initial data expected in Q4. The stock rose 7% to $12.31, ending a three-quarter decline, as traders noted its HQ lease and upcoming milestones.
Sellas Life Sciences (SLS) fell 16.6% in Q3 due to delays in AML treatment data. Despite this, shares rose 6.95% on Q3 window-dressing. The company's GPS treatment study awaits the 80th patient death for results. SLS009 showed promising data in pancreatic cancer trials. Q2 losses widened to $9.6M, with no revenue. Hedge funds increased holdings to $79.7M, with Anson Investments as the largest stakeholder.
Sellas Life Sciences (SLS) stock rose 2% to $13.76 after updating its SLS009 trial for AML, which includes drugs from AbbVie (ABBV), Roche (RHHBY), and Bristol Myers Squibb (BMY). The trial, in early-to-mid stages, tests SLS009 alone and in combination. SLS focuses on its Phase 3 Regal trial, nearing final analysis. CEO Angelos Stergiou addressed criticism, emphasizing data over noise. Retail sentiment remains bullish.
Johnson & Johnson and Pfizer are targeting early-stage cancer assets, focusing on Sellas Life Sciences (SLS), ImmunityBio (IBRX), and Iovance Biotherapeutics (IOVA). SLS's SLS009 showed 46%-50% response rates in AML, while Iovance expects lung-cancer data in Q4. J&J's CEO highlighted M&A interest in early-stage opportunities, with recent deals like Halda Therapeutics and Firefly Bio. IOVA, IBRX, and SLS stocks rose 8%, 6%, and 2% respectively on Monday.
U.S. stock futures dropped due to U.S.-Iran tensions, overshadowing earnings season and economic data. Nasdaq futures fell 1.2%, S&P 500 futures declined 0.4%. SK Hynix (SKHYV) fell 15% post-debut. Oil stocks rose on geopolitical risks. Micron (MU) and Tesla (TSLA) dropped on profit-taking and competitive pressures. Microsoft (MSFT) saw defensive buying.
Sellas Life Sciences (SLS) reported increased cash reserves to $135.8 million after warrant exercises, extending its capital runway. CEO Angelos Stergiou highlighted this as enabling key milestones and growth. The company's shares were down 2.5% at the time of writing. Investors focus on the Regal trial of Galinpepimut-S (GPS) in AML, with 78 of 80 events recorded, and SLS009, a Phase 2 AML drug candidate with data expected later this year.
